CHLOE EQ is designed to enable Embryo Viability Assessment, which supports the prediction of blastulation, implantation and ploidy and, ranks embryos in order of priority
Israeli AI start-up Fairtility has obtained a CE mark for its AI-powered decision support tool, dubbed CHLOE EQ, for use in in-vitro fertilisation (IVF) fertility clinics across Europe.
CHLOE EQ has been developed to enable Embryo Viability Assessment, which supports the prediction of blastulation, implantation and ploidy and, ranks embryos in order of priority.
In addition, the tool also provides automatic annotations for morphokinetic and PN count which support fertilisation assessment, said the company.
Fairtility clinical affairs VP and embryology expert Dr Cristina Hickman said: “Traditionally, embryo evaluation and selection has been a manual process, limiting patient access to treatment while also opening the door for human error.
“One of the key advantages that CHLOE EQ, the transparent AI-driven embryo quality assessment tool, was designed to offer is accuracy and consistency in assessment.
“CHLOE’s proprietary AI-based algorithms become more accurate the more data it gathers, leading to uniform and accurate embryo assessment.”
CHLOE EQ provides information that helps embryologists and IVF professionals in prioritising the embryo for treatment, particularly when there are multiple embryos deemed suitable.
The tool enhances the workflow of embryologists by automating the manual steps, including written observations into patients’ electronic medical records (EMR).
CHLOE EQ enables embryologists to verify its automatic annotations, which are then immediately integrated from the Time Lapse Incubator (TLI) directly into the EMR.
The regulatory approval was granted under the European Medical Devices Regulation (MDR) which serves as the new legal framework for medical devices in Europe.
Fairtility CEO and co-founder Eran Eshed said: “Having gained regulatory acknowledgement in Europe, under the more stringent directive that the CE MDR provides, we are now commercially launching CHLOE EQ in clinics across the EU while continuing to uphold the highest standard of this classification.
“With the EU IVF market size estimated to reach over $2bn by 2027, we see tremendous opportunities to demonstrate the clinical efficacy and impact of CHLOE EQ ahead of US market entry.”